AstraZeneca appoints Fante to head U.S.
Executive Summary
U.K drug maker names Rich Fante to U.S. President Nov. 13. Fante, a 13-year veteran of the firm, was most recently VP-brand strategy and portfolio operations, leading development and marketing for all AstraZeneca brands in the U.S. Fante takes the helm from Tony Zook, CEO of North America and head of global marketing, whose role was expanded in July to include oversight of MedImmune after CEO David Mott left the firm one year after AstraZeneca's $15.6 billion buyout (1"The Pink Sheet" DAILY, June 26, 2008)
You may also be interested in...
MedImmune’s CEO Stepping Down
AstraZeneca’s North American CEO Zook will assume responsibilities until a successor is hired.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.